Erratum to: 'Structural genomics and drug discovery: all in the family' [Curr Opin Chem Biol (2008) 12:32-39] (DOI:10.1016/j.cbpa.2008.01.045);Structural genomics and drug discovery: all in the family

Current Opinion in Chemical Biology

Volumn 12, Issue 1, 2008, Pages 32-39

  Weigelt, Johan ^a   McBroom Cerajewski, Linda DB ^b   Schapira, Matthieu ^b   Zhao, Yong ^b   Arrowmsmith, Cheryl H ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ANTIMALARIAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; LIGAND; METHYLTRANSFERASE; OXIDOREDUCTASE; PHOSPHATE; PHOSPHOTRANSFERASE; PROTEIN TYROSINE PHOSPHATASE; RUBOXISTAURIN; SULFOTRANSFERASE;

BACTERIUM; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENZYME METABOLISM; HUMAN; NONHUMAN; OSTEOLYSIS; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN STRUCTURE; PROTOZOON; REVIEW; STRUCTURAL GENOMICS; VIRUS;

BACTERIA (MICROORGANISMS); PROTOZOA;

EID: 40849141980     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.03.007     Document Type: Erratum

References (55)

1. Congreve M., Murray C.W., and Blundell T.L. Structural biology and drug discovery. Drug Discov Today 10 (2005) 895-907. A very thorough review and up-to-date description of the utility of structural biology in drug discovery.
2. Chandonia J.M., and Brenner S.E. The impact of structural genomics: expectations and outcomes. Science 311 (2006) 347-351. A quantitative evaluation of the impact of structural genomics on structural biology.
3. Gileadi O., Knapp S., Lee W.H., Marsden B.D., Muller S., Niesen F.H., Kavanagh K.L., Ball L.J., von Delft F., Doyle D.A., et al. The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. J Struct Funct Genomics 8 (2007) 107-119
4. Yokoyama S., Terwilliger T.C., Kuramitsu S., Moras D., and Sussman J.L. RIKEN aids international structural genomics efforts. Nature 445 (2007) 21
5. Matthews B.W. Protein structure initiative: getting into gear. Nat Struct Mol Biol 14 (2007) 459-460
6. Baker E.N. Structural genomics as an approach towards understanding the biology of tuberculosis. J Struct Funct Genomics 8 (2007) 57-65
7. Coutard B, Gorbalenya S, Snijder E, Leontovich A, Poupon A, De Lamballerie X, Charrel R, Gould E, Gunther S, Norder H, et al.: The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res 2007, Nov 29 [Epub ahead of print]. Description of the gene family approach as applied to known and emerging human viral pathogens. This project focuses on conserved viral replicases using structural biology and pre-lead discovery to propose active scaffolds for antiviral compounds.
8. Mehlin C. Structure-based drug discovery for Plasmodium falciparum. Comb Chem High Throughput Screen 8 (2005) 5-14
9. Vedadi M., Lew J., Artz J., Amani M., Zhao Y., Dong A., Wasney G.A., Gao M., Hills T., Brokx S., et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol 151 (2007) 100-110
10. Jhoti H., Cleasby A., Verdonk M., and Williams G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11 (2007) 485-493. This review describes current developments in fragment-based screening, an approach that relies heavily on structural information as well as structural genomics technologies, as a tool for drug discovery.
11. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34 (2006) D668-D672
12. Abagyan R., Lee W.H., Raush E., Budagyan L., Totrov M., Sundstrom M., and Marsden B.D. Disseminating structural genomics data to the public: from a data dump to an animated story. Trends Biochem Sci 31 (2006) 76-78
13. Avvakumov G.V., Walker J.R., Xue S., Finerty Jr. P.J., Mackenzie F., Newman E.M., and Dhe-Paganon S. Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J Biol Chem 281 (2006) 38061-38070
14. Bitto E., Bingman C.A., Wesenberg G.E., McCoy J.G., and Phillips Jr. G.N. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104 (2007) 456-461
15. Bullock A.N., Debreczeni J.E., Fedorov O.Y., Nelson A., Marsden B.D., and Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem 48 (2005) 7604-7614. A prime example of highly significant information being provided by structural genomics. This paper contains a description of the structure of a key target and its interaction with inhibitors.
16. Bunkoczi G., Salah E., Filippakopoulos P., Fedorov O., Muller S., Sobott F., Parker S.A., Zhang H., Min W., Turk B.E., et al. Structural and functional characterization of the human protein kinase ASK1. Structure 15 (2007) 1215-1226
17. Card G.L., Peterson N.A., Smith C.A., Rupp B., Schick B.M., and Baker E.N. The crystal structure of Rv1347c, a putative antibiotic resistance protein from Mycobacterium tuberculosis, reveals a GCN5-related fold and suggests an alternative function in siderophore biosynthesis. J Biol Chem 280 (2005) 13978-13986. This structure of this protein indicates an alternative annotation and suggests it may be a good TB target.
18. Davis T.L., Walker J.R., Finerty Jr. P.J., Mackenzie F., Newman E.M., and Dhe-Paganon S. The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition. J Mol Biol 366 (2007) 216-229
19. Deng J., Ernst N.L., Turley S., Stuart K.D., and Hol W.G. Structural basis for UTP specificity of RNA editing TUTases from Trypanosoma brucei. EMBO J 24 (2005) 4007-4017
20. Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A., Fedorov O., Deacon S.W., Peterson J.R., and Knapp S. Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15 (2007) 201-213
21. Eswaran J., von Kries J.P., Marsden B., Longman E., Debreczeni J.E., Ugochukwu E., Turnbull A., Lee W.H., Knapp S., and Barr A.J. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochem J 395 (2006) 483-491
22. Hong B.S., Senisterra G., Rabeh W.M., Vedadi M., Leonardi R., Zhang Y.M., Rock C.O., Jackowski S., and Park H.W. Crystal structures of human pantothenate kinases. Insights into allosteric regulation and mutations linked to a neurodegeneration disorder. J Biol Chem 282 (2007) 27984-27993
23. Kantardjieff K.A., Vasquez C., Castro P., Warfel N.M., Rho B.S., Lekin T., Kim C.Y., Segelke B.W., Terwilliger T.C., and Rupp B. Structure of pyrR (Rv1379) from Mycobacterium tuberculosis: a persistence gene and protein drug target. Acta Crystallogr D Biol Crystallogr 61 (2005) 355-364
24. Kavanagh K.L., Dunford J.E., Bunkoczi G., Russell R.G., and Oppermann U. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 281 (2006) 22004-22012
25. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., Rogers M.J., Russell R.G., and Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 103 (2006) 7829-7834. This paper concerns the structural interpretation of the inhibitory mechanism of a drug class, and provides clues for future development.
26. Guo R.T., Cao R., Liang P.H., Ko T.P., Chang T.H., Hudock M.P., Jeng W.Y., Chen C.K., Zhang Y., Song Y., et al. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A 104 (2007) 10022-10027. This paper reveals multiple binding modes for identical inhibitors with the same enzyme and across related enzymes.
27. Krajewski W.W., Collins R., Holmberg-Schiavone L., Jones T.A., Karlberg T., and Mowbray S.L. Crystal structures of mammalian glutamine synthetases illustrate substrate-induced conformational changes and provide opportunities for drug and herbicide design. J Mol Biol 375 1 (2007) 217-228. The structure of the human enzyme complements earlier work on the TB and maize enzymes, and provides a framework that can be utilized to develop TB specific drugs and/or non-toxic herbicides.
28. Kursula P., Flodin S., Ehn M., Hammarstrom M., Schuler H., Nordlund P., and Stenmark P. Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. Acta Crystallogr Sect F Struct Biol Cryst Commun 62 (2006) 613-617
29. Kursula P., Schuler H., Flodin S., Nilsson-Ehle P., Ogg D.J., Savitsky P., Nordlund P., and Stenmark P. Structures of the hydrolase domain of human 10-formyltetrahydrofolate dehydrogenase and its complex with a substrate analogue. Acta Crystallogr D Biol Crystallogr 62 (2006) 1294-1299
30. Luzhkov V.B., Selisko B., Nordqvist A., Peyrane F., Decroly E., Alvarez K., Karlen A., Canard B., and Qvist J. Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2′O)-methyltransferase. Bioorg Med Chem 15 (2007) 7795-7802
31. Maresso A.W., Wu R., Kern J.W., Zhang R., Janik D., Missiakas D.M., Duban M.E., Joachimiak A., and Schneewind O. Activation of inhibitors by sortase triggers irreversible modification of the active site. J Biol Chem 282 (2007) 23129-23139
32. Ng S.S., Kavanagh K.L., McDonough M.A., Butler D., Pilka E.S., Lienard B.M., Bray J.E., Savitsky P., Gileadi O., von Delft F., et al. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature 448 (2007) 87-91. Histone demethylases are a newly recognized potential target family. The authors describe the structure of a ternary complex of a human demethylase which reveals why it reacts with a specific methyl mark, and serves as a template for future screening or drug design programs.
33. Rellos P., Ivins F.J., Baxter J.E., Pike A., Nott T.J., Parkinson D.M., Das S., Howell S., Fedorov O., Shen Q.Y., et al. Structure and regulation of the human Nek2 centrosomal kinase. J Biol Chem 282 (2007) 6833-6842
34. Robien M.A., Bosch J., Buckner F.S., Van Voorhis W.C., Worthey E.A., Myler P., Mehlin C., Boni E.E., Kalyuzhniy O., Anderson L., et al. Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 Å resolution reveals intriguing extra electron density in the active site. Proteins 62 (2006) 570-577
35. Schuetz A., Min J., Antoshenko T., Wang C.L., Allali-Hassani A., Dong A., Loppnau P., Vedadi M., Bochkarev A., Sternglanz R., et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15 (2007) 377-389
36. Stenmark P., Kursula P., Flodin S., Graslund S., Landry R., Nordlund P., and Schuler H. Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J Biol Chem 282 (2007) 3182-3187
37. 2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A 103 (2006) 2611-2616
38. Wallden K., Stenmark P., Nyman T., Flodin S., Graslund S., Loppnau P., Bianchi V., and Nordlund P. Crystal structure of human cytosolic 5′-nucleotidase II: insights into allosteric regulation and substrate recognition. J Biol Chem 282 (2007) 17828-17836
39. Wu H., Min J., Ikeguchi Y., Zeng H., Dong A., Loppnau P., Pegg A.E., and Plotnikov A.N. Structure and mechanism of spermidine synthases. Biochemistry 46 (2007) 8331-8339
40. Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., Zhao Q., Zhou Z., Pei D., Ziebuhr J., et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3 (2005) e324
41. Federov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, Schwaller J, Sundstrom M, Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 2007, 104:20523-20528. This paper demonstrates the synergy between chemogenomic approaches for drug discovery and the family based approach to structural genomics. The availability of purified recombinant human protein kinases facilitated an in vitro profiling experiment of binding of a large test set of kinase directed compounds, revealing inhibitor and protein promiscuities, as well as patterns of cross reactivity.
42. Egloff M.P., Benarroch D., Selisko B., Romette J.L., and Canard B. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J 21 (2002) 2757-2768
43. Guo K., Lukacik P., Papagrigoriou E., Meier M., Lee W.H., Adamski J., and Oppermann U. Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme: a novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase. J Biol Chem 281 (2006) 10291-10297
44. Tempel W., Rabeh W.M., Bogan K.L., Belenky P., Wojcik M., Seidle H.F., Nedyalkova L., Yang T., Sauve A.A., Park H.W., et al. Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol 5 (2007) e263
45. Bello A.M., Poduch E., Fujihashi M., Amani M., Li Y., Crandall I., Hui R., Lee P.I., Kain K.C., Pai E.F., et al. A potent, covalent inhibitor of orotidine 5′-monophosphate decarboxylase with antimalarial activity. J Med Chem 50 (2007) 915-921
46. Zhang R., Wu R., Joachimiak G., Mazmanian S.K., Missiakas D.M., Gornicki P., Schneewind O., and Joachimiak A. Structures of sortase B from Staphylococcus aureus and Bacillus anthracis reveal catalytic amino acid triad in the active site. Structure 12 (2004) 1147-1156
47. Vedadi M., Niesen F.H., Allali-Hassani A., Fedorov O.Y., Finerty Jr. P.J., Wasney G.A., Yeung R., Arrowsmith C., Ball L.J., Berglund H., et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A 103 (2006) 15835-15840. This paper describes the usefulness of thermal stability screens to identify solution conditions that promote protein stability. Although the main focus of the paper is structure determination, the methods are clearly applicable to other purposes such as biochemical analysis and HTS-assay development, etc.
48. Berry I., Dym O., Esnouf R., Harlos K., Meged R., Perrakis A., Sussman J., Walter T., Wilson J., and Messerschmidt A. SPINE high-throughput crystallization, crystal imaging and recognition techniques: current state, performance analysis, new technologies and future aspects. Acta Crystallogr D Biol Crystallogr 62 (2006) 1137-1149
49. Bosch J., Robien M.A., Mehlin C., Boni E., Riechers A., Buckner F.S., Van Voorhis W.C., Myler P.J., Worthey E.A., DeTitta G., et al. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem 49 (2006) 5939-5946
50. Bredel M., and Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 5 (2004) 262-275
51. Harris C.J., and Stevens A.P. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 11 (2006) 880-888
52. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 152 (2007) 38-52
53. Marsden BD, Knapp S: Doing more than just the structure - Structural Genomics in kinase drug discovery. Curr Opin Chem Biol 2008, in press, doi:10.1016/j.cbpa.2008.01.042.
54. Allali-Hassani A., Pan P.W., Dombrovski L., Najmanovich R., Tempel W., Dong A., Loppnau P., Martin F., Thonton J., Edwards A.M., et al. Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol 5 (2007) e97. An example of family wide profiling of protein-ligand interactions and their structural interpretation facilitated by structural genomics.
55. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 5 (2006) 993-996. An analysis of current and potential drug targets. The conclusions underline the importance of the gene family and chemogenomic approach.